Zydus Lifesciences Limited is acquiring an 85.6% controlling stake in French orthopedic firm Amplitude Surgical SA for €256.8 million to expand into the global MedTech market.

Information on the Target

Zydus Lifesciences Limited has recently entered into exclusive negotiations to acquire an 85.6% controlling stake in Amplitude Surgical SA, a leading French MedTech firm specializing in lower-limb orthopedic technologies. The total value of the deal is €256.8 million (over ₹2,400 crore). Following this acquisition, Zydus plans to file a mandatory cash tender offer for the outstanding shares of Amplitude at €6.25 per share, potentially resulting in a full acquisition valued at approximately €300 million (₹2,850 crore) and a subsequent delisting from Euronext Paris.

Amplitude Surgical is renowned for its innovations in knee and hip prostheses, which are crucial for patients with damaged or worn-out joints. The company has been steadily expanding its international footprint, operating in over 30 countries as of June 2024, and boasts a workforce of 428 employees. Backed by PAI Partners through its Mid-Market Fund, Amplitude has experienced robust growth driven by advancements in product development, expansion into new markets, and significant investments in research and development (R&D) and manufacturing capabilities.

Industry Overview in France

The healthcare and MedTech sector in France is characterized by rapid innovation and substantial investment in research. France boasts a strong commitment to healthcare advance